Research progress of chimeric antigen receptor T cells in the treatment of primary liver cancer
10.3969/j.issn.1001-6325.2018.07.024
- VernacularTitle:嵌合抗原受体T细胞治疗原发性肝癌的研究进展
- Author:
Yang XU
1
;
Ya-Min ZHANG
;
Jian WANG
;
Zi-Rong LIU
Author Information
1. 天津医科大学第一中心临床学院
- Keywords:
primary liver cancer;
immune therapy;
CAR-T therapy;
target antigen
- From:
Basic & Clinical Medicine
2018;38(7):1016-1019
- CountryChina
- Language:Chinese
-
Abstract:
CAR-T technology as a kind of immunotherapy, from the earliest generation of the first to the current fourth generation, its cytotoxic, anti-tumor immune effect greatly enhanced, but also challenged by safety issues.It shows a certain advantage in the therapy of Hepatocellular carcinoma. It indicates that the era of precise individual-ized liver cancer treatment, immune therapy, especially CAR-T technology combined with surgery, radiotherapy and chemotherapy, local treatment and other comprehensive treatment will play a more powerful role.
